تقارير التقييم العلمي PAR

الإدارة المركزية للمستحضرات الحيوية والمبتكرة والدراسات الإكلينيكية

الإدارة المركزية للمستحضرات الحيوية والمبتكرة والدراسات الإكلينيكية

Publish Date

Marketing Authorization Holder (MAH)

Dosage Form Scientific Name Product Name
14/12/2023   Solution for injection in prefilled syringe
for subcutaneous administration
Teriparatide (r-PTH 1-34) Bonosome r-DNA  1
18/3/2024 CSL Behring GmbH Emil-von-Behring-Straβe 76, D-35041 Marburg-Germany Powder and solvent for solution for injection  single chain coagulation factor VIII (rVIII-single chain Afstyla 2
18/3/2024 Celltrion, Inc., 20 Academy-ro 51 beon-gil, Yeonsu-gu Incheon, Republic of Korea. Lypholized Powder and solvent for solution for injection Trastuzumab150mg Herzuma 3
18/3/2024

Sanofi Pasteur Inc., 1 Discovery Drive, Swiftwater, PA 18370 - USA

Solution for injection

Meningococcal group A, C, W135, Y conjugated to Tetanus Toxoid

MenQuadfi 4
18/3/2024

Accord Healthcare Limited Sage House, 319 Pinner Road North Harrow, Middlesex HA1 4HF - United Kingdom

Solution for injection

Pegfilgrastim 6mg/0.6ml Solution

Pelgraz 5
18/3/2024

Sanofi Winthrop Industrie, 82 Avenue Raspail, 94250 Gentillty - France

Concentrate for solution for Infusion

Isatuximab100 mg/5ml

Isatuximab 500 mg/25m

Sarclisa 100&500 MG 6
18/3/2024

GlaxoSmithKline Biologicals SA 89, rue de l"Institut, B-1330 Rixensart - BELGIUM

Powder and suspension 

for suspension for injection

Varicella Zoster Virus glycoprotein E antigen 50 mcg/0.5ml

Shingrix vaccine 7
18/3/2024

AbbVie Deutschland GmbH & Co. KG, Knollstrasse, 67061 Ludwigshafen, Germany.

Solution for injection

Risankizumab

150 mg

Skyrizi 150mg 8

جميع الحقوق محفوظة © 2021